Key statistics dashboard for Akebia Therapeutics, Inc. (AKBA). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials.
Stock Data
| Price | $0.92 |
| Market Cap | $246M |
| Enterprise Value | $144.6M |
| Beta | 0.37 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -8.36 |
| Price / Book | 9.73 |
| P/S | 1.11 |
| EV/EBITDA | -8.03 |
| EV/Sales | 0.66 |
| EV/FCF | 3.59 |
| P/FCF | 6.02 |
| Earnings Yield | -11.99% |
| FCF Yield | 16.34% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 79.48% |
| EBIT Margin | -9.08% |
| EBITDA Margin | -8.22% |
| Operating Margin | -6.91% |
| Net Margin | -13.54% |
| Return on Equity | -93.74% |
| Return on Assets | -8.48% |
| Return on Invested Capital | -7.08% |
| Return on Capital Employed | -8.01% |
Financial Health
| Current Ratio | 1.43 |
| Quick Ratio | 1.35 |
| Cash Ratio | 0.97 |
| Debt / Equity | 2.16 |
| Debt / Assets | 15.43% |
| Net Debt / EBITDA | 5.64 |
| Interest Coverage | -1.90 |
| Piotroski F-Score | 6 |
| Altman Z-Score | -4.63 |
Per-Share Data
| Revenue per share | 0.81 |
| Book Value per share | 0.09 |
| Cash per share | 0.58 |
| FCF per share | 0.15 |
| Tangible Book Value per share | -0.13 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 7 |
| Hold | 4 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 12 |
| Avg rating (1-5) | 0.50 |
Related companies: CMPX · CRVS · FDMT · GOSS · KALV · OLMA · PRTA
Explore sector: Healthcare · Biotechnology
More sections of AKBA: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks